Literature DB >> 2516083

Activity of cefepime, ceftazidime, and ceftizoxime against mutants of Enterobacteriaceae and Pseudomonas aeruginosa derepressed for class I beta-lactamase.

C C Knapp1, J A Washington.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2516083     DOI： 10.1093/jac/24.6.1011

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  7 in total

1.  Efficacies of cefepime, ceftazidime, and imipenem alone or in combination with amikacin in rats with experimental pneumonia due to ceftazidime-susceptible or -resistant Enterobacter cloacae strains.

Authors:  O Mimoz; A Jacolot; S Leotard; N Hidri; K Samii; P Nordmann; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

2.  Development of test panel of beta-lactamases expressed in a common Escherichia coli host background for evaluation of new beta-lactam antibiotics.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

3.  Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of Enterobacter cloacae.

Authors:  O Mimoz; S Leotard; A Jacolot; C Padoin; K Louchahi; O Petitjean; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

Review 4.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

5.  Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime.

Authors:  J A Washington; R N Jones; E H Gerlach; P R Murray; S D Allen; C C Knapp
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

6.  Combination effect of SCE-2787 and cefepime with aminoglycosides on nosocomial gram-negative bacteria.

Authors:  J Hübner; D Hartung; A Kropec; F D Daschner
Journal:  Infection       Date:  1991 May-Jun       Impact factor: 3.553

Review 7.  Future directions in antimicrobial chemotherapy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1992-08-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.